| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and u... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., July 30, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ... |
| 18 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., Apr. 29, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., Feb. 12, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
J.P. Morgan Healthcare Conference 2026 Agios Pharmaceuticals Brian Goff, Chief Executive Officer 14 January 2026 Exhibit 99.2 |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., October 30, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results a... |
| 04 Aug 2025 |
8-K: Regulation FD Disclosure
Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) is aware of the securities analyst report published on August 4, 2025 (the “Analyst Report”), detailing recent PYRUKYND® data from the U.S. Food and Drug Administration’s (“FDA”) Adv... |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
CAMBRIDGE, Mass., July 31, 2025 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ... |
| 08 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 18 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, |
| 13 Feb 2025 |
8-K: Results of Operations and Financial Condition
– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with |
| 13 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
J.P. Morgan Healthcare Conference Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 15, 2025 Exhibit 99.2 |
| 06 Jan 2025 |
8-K: Regulation FD Disclosure
On January 3, 2025, the U.S. Food and Drug Administration approved an update to the U.S. Prescribing Information (“USPI”) for PYRUKYND® (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase (“PK”) deficiency. T... |
| 31 Oct 2024 |
8-K: Results of Operations and Financial Condition
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – |
| 01 Aug 2024 |
8-K: Results of Operations and Financial Condition
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; |
| 20 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
Agios Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 20, 2024 (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting. |
| 28 May 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net |
Loading...